Literature DB >> 7899828

Biological implications of HLA-DR expression in tumours.

T Cabrera1, F Ruiz-Cabello, F Garrido.   

Abstract

HLA-DR antigens show restricted tissue distribution in comparison with the more extensive expression of HLA class I molecules. This constitutive expression is genetically controlled by well-defined mechanisms. In addition, DR antigen expression can be induced by a variety of cytokines through different molecular genetic events that convert DR-negative epithelia into positive cells. In this review we analyse the two major pathological situations in which abnormal DR expression occurs: autoimmune diseases and tumour development. We hypothesize that conversion to DR-positivity may produce two opposite effects in both clinical situations: (1) a useful one in tumours associated with a good prognosis; and (2) a harmful one in autoimmune diseases with increased tissue damage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7899828     DOI: 10.1111/j.1365-3083.1995.tb03584.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  17 in total

Review 1.  The opposing roles of CD4+ T cells in anti-tumour immunity.

Authors:  Tomasz Ahrends; Jannie Borst
Journal:  Immunology       Date:  2018-04-27       Impact factor: 7.397

2.  HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Authors:  Giuseppe Sconocchia; Serenella Eppenberger-Castori; Inti Zlobec; Eva Karamitopoulou; Roberto Arriga; Andrea Coppola; Sara Caratelli; Giulio Cesare Spagnoli; Davide Lauro; Alessandro Lugli; Junyi Han; Giandomenica Iezzi; Cristina Ferrone; Amedeo Ferlosio; Luigi Tornillo; Raoul Droeser; Piero Rossi; Antonio Attanasio; Soldano Ferrone; Luigi Terracciano
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

3.  Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.

Authors:  T D Armstrong; V K Clements; B K Martin; J P Ting; S Ostrand-Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.

Authors:  T Rodríguez; R Méndez; A Del Campo; N Aptsiauri; J Martín; G Orozco; G Pawelec; D Schadendorf; F Ruiz-Cabello; F Garrido
Journal:  Immunogenetics       Date:  2006-12-20       Impact factor: 2.846

5.  HLA-DRB1 allele polymorphism and nasopharyngeal carcinoma risk: a meta-analysis.

Authors:  Keqing Yao; Shujuan Yang; Jun Shen; Ran Zhang; Lianqing Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-17       Impact factor: 2.503

6.  CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Authors:  D Mumberg; P A Monach; S Wanderling; M Philip; A Y Toledano; R D Schreiber; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

7.  CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches.

Authors:  Elise Ramia; Anna Maria Chiaravalli; Farah Bou Nasser Eddine; Alessandra Tedeschi; Fausto Sessa; Roberto S Accolla; Greta Forlani
Journal:  Oncoimmunology       Date:  2018-11-26       Impact factor: 8.110

Review 8.  HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.

Authors:  M Campoli; S Ferrone
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

Review 9.  Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice?

Authors:  Leonidas Alevizos; Ilias P Gomatos; Spyridon Smparounis; Manousos M Konstadoulakis; Georgios Zografos
Journal:  Can J Surg       Date:  2012-04       Impact factor: 2.089

10.  Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer.

Authors:  Eva-Maria Surmann; Anita Y Voigt; Sara Michel; Kathrin Bauer; Miriam Reuschenbach; Soldano Ferrone; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Cancer Immunol Immunother       Date:  2014-12-02       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.